Comparative Pharmacology
Head-to-head clinical analysis: PRISMASOL BK 0 3 5 IN PLASTIC CONTAINER versus PRISMASOL BK 4 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISMASOL BK 0 3 5 IN PLASTIC CONTAINER versus PRISMASOL BK 4 2 5 IN PLASTIC CONTAINER.
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER vs PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PrismaSol is a sterile solution containing electrolytes and bicarbonate buffer, used in continuous renal replacement therapy (CRRT) to correct fluid and electrolyte imbalances and acid-base disturbances. It acts as a replacement fluid to maintain electrolyte and acid-base homeostasis by providing physiologic concentrations of electrolytes and a bicarbonate buffer.
Prismasol BK 4/2.5 is a bicarbonate-buffered hemofiltration solution used in continuous renal replacement therapy (CRRT). It provides electrolyte and buffer replacement to correct metabolic acidosis and maintain acid-base balance, with no direct pharmacological activity. Its mechanism of action is based on the physical removal of solutes and water via convection and diffusion across a hemofilter membrane.
Continuous renal replacement therapy (CRRT): 2000 mL bag, flow rate 1000-2000 mL/h (dose tailored to target electrolyte balance and acid-base status). For continuous ambulatory peritoneal dialysis (CAPD): 2000 mL per exchange, 4 exchanges per day (individualized). Intravenous or intraperitoneal route.
Administered only via an extracorporeal circuit as part of continuous venovenous hemofiltration (CVVH), hemodialysis (CVVHD), or hemodiafiltration (CVVHDF). The dose is prescribed as effluent flow rate, typically 20–35 mL/kg/hour. For a 70 kg patient, total effluent flow (replacement fluid plus dialysate) is 1400–2450 mL/hour; the proportion of PRISMASOL BK 4/2.5 used as replacement fluid and/or dialysate is adjusted to achieve target fluid removal and metabolic control. Total daily volume commonly 24–72 L.
None Documented
None Documented
Not applicable as the drug is not systemically present; half-life refers to solutes in the patient's blood during CRRT, which is determined by the therapy and patient factors, not the solution.
Not applicable as a drug; the half-life of infused bicarbonate is approximately 15 minutes due to rapid buffering and renal excretion. Potassium's half-life is about 1-1.5 hours in normal renal function but prolonged in renal failure.
Not applicable; PRISMASOL BK 0/3.5 is a renal replacement therapy solution not systemically absorbed. Solutes are removed via continuous renal replacement therapy (CRRT) circuit, with clearance dependent on operational parameters.
PRISMASOL BK 4/2.5 is a bicarbonate-buffered hemodialysis solution; its components are electrolytes and buffer. Elimination is primarily via dialysis: the solution itself is not systemically absorbed; rather, solutes are removed during therapy. Endogenous potassium is excreted renally (95%) and fecally (5%). Bicarbonate is regenerated via renal and metabolic processes.
Category C
Category C
Dialysis Solution
Dialysis Solution